Humana Inc. (HUM) is experiencing
mixed fundamentals in the market, creating a negative sentiment, despite its stocks being acquired by multiple entities such as Charles Schwab Investment Management, Quest Partners, the Ontario Teachers Pension Plan Board, and others. It has seen a rise in stock price by
4.1% but suffered a dip due to rumors of merger with Cigna. Pomerantz Law Firm is investigating on behalf of its investors. The company's
Medicare and primary care strength helped it top estimates but its ratings have plunged, sending a red flag. Humanaβs financial performance beat Q3 estimates on growing premiums and cost management, while Mawer Investment Management and PNC Financial Services Group Inc. reduced their positions. Significant Medicare Advantage data also led to a dip in stock price. Amidst this, Humana is suiting to reverse high-stakes cut to Medicare ratings. Humanaβs Q3 earnings outperformed key metrics and announced a dividend of
$0.885. The company offered strong Q4 EPS guidance and raised its price target. Cigna ended speculations of its merger causing HUM to slip while analysts updated new forecasts on its earnings beat. Its shares have seen a massive decline over the last year.
Humana HUM News Analytics from Wed, 31 Jul 2024 07:00:00 GMT to Sat, 23 Nov 2024 12:00:22 GMT -
Rating -3
- Innovation 0
- Information 5
- Rumor -6
